Advertisement

Neurocritical Care

, 15:329 | Cite as

Hemodynamic Management of Subarachnoid Hemorrhage

  • Miriam M. TreggiariEmail author
  • Participants in the International Multi-disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage
Review

Abstract

Hemodynamic augmentation therapy is considered standard treatment to help prevent and treat vasospasm and delayed cerebral ischemia. Standard triple-H therapy combines volume expansion (hypervolemia), blood pressure augmentation (hypertension), and hemodilution. An electronic literature search was conducted of English-language papers published between 2000 and October 2010 that focused on hemodynamic augmentation therapies in patients with subarachnoid hemorrhage. Among the eligible reports identified, 11 addressed volume expansion, 10 blood pressure management, 4 inotropic therapy, and 12 hemodynamic augmentation in patients with unsecured aneurysms. While hypovolemia should be avoided, hypervolemia did not appear to confer additional benefits over normovolemic therapy, with an excess of side effects occurring in patients treated with hypervolemic targets. Overall, hypertension was associated with higher cerebral blood flow, regardless of volume status (normo- or hypervolemia), with neurological symptom reversal seen in two-thirds of treated patients. Limited data were available for evaluating inotropic agents or hemodynamic augmentation in patients with additional unsecured aneurysms. In the context of sparse data, no incremental risk of aneurysmal rupture has been reported with the induction of hemodynamic augmentation.

Keywords

Hemodilution Hypertension Hypervolemia Inotropic Volume expansion 

References

  1. 1.
    Nakagawa A, Su CC, Sato K, Shirane R. Evaluation of changes in circulating blood volume during acute and very acute stages of subarachnoid hemorrhage: implications for the management of hypovolemia. J Neurosurg. 2002;97:268–71.PubMedCrossRefGoogle Scholar
  2. 2.
    Ract C, Vigue B. Comparison of the cerebral effects of dopamine and norepinephrine in severely head-injured patients. Intensive Care Med. 2001;27:101–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Steiner LA, Johnston AJ, Czosnyka M, et al. Direct comparison of cerebrovascular effects of norepinephrine and dopamine in head-injured patients. Crit Care Med. 2004;32:1049–54.PubMedCrossRefGoogle Scholar
  4. 4.
    Myburgh JA, Upton RN, Grant C, Martinez A. A comparison of the effects of norepinephrine, epinephrine, and dopamine on cerebral blood flow and oxygen utilisation. Acta Neurochir Suppl. 1998;71:19–21.PubMedGoogle Scholar
  5. 5.
    Treggiari MM, Deem S. Which H is the most important in triple-H therapy for cerebral vasospasm? Curr Opin Crit Care. 2009;15:83–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Lennihan L, Mayer SA, Fink ME, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2000;31:383–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Egge A, Waterloo K, Sjoholm H, Solberg T, Ingebrigtsen T, Romner B. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery. 2001;49:593–605.PubMedGoogle Scholar
  8. 8.
    Mori K, Arai H, Nakajima K, Tajima A, Maeda M. Hemorheological and hemodynamic analysis of hypervolemic hemodilution therapy for cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 1995;26:1620–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Muench E, Horn P, Bauhuf C, et al. Effects of hypervolemia and hypertension on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation after subarachnoid hemorrhage. Crit Care Med. 2007;35:1844–51.PubMedCrossRefGoogle Scholar
  10. 10.
    Raabe A, Beck J, Keller M, Vatter H, Zimmermann M, Seifert V. Relative importance of hypertension compared with hypervolemia for increasing cerebral oxygenation in patients with cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg. 2005;103:974–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Ekelund A, Reinstrup P, Ryding E, et al. Effects of iso- and hypervolemic hemodilution on regional cerebral blood flow and oxygen delivery for patients with vasospasm after aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2002;144:703–12.CrossRefGoogle Scholar
  12. 12.
    Jost SC, Diringer MN, Zazulia AR, et al. Effect of normal saline bolus on cerebral blood flow in regions with low baseline flow in patients with vasospasm following subarachnoid hemorrhage. J Neurosurg. 2005;103:25–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Yamakami I, Isobe K, Yamaura A. Effects of intravascular volume expansion on cerebral blood flow in patients with ruptured cerebral aneurysms. Neurosurgery. 1987;21:303–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Suarez JI, Shannon L, Zaidat OO, et al. Effect of human albumin administration on clinical outcome and hospital cost in patients with subarachnoid hemorrhage. J Neurosurg. 2004;100:585–90.PubMedCrossRefGoogle Scholar
  15. 15.
    Tseng MY, Al-Rawi PG, Pickard JD, Rasulo FA, Kirkpatrick PJ. Effect of hypertonic saline on cerebral blood flow in poor-grade patients with subarachnoid hemorrhage. Stroke. 2003;34:1389–96.PubMedCrossRefGoogle Scholar
  16. 16.
    Tseng MY, Al-Rawi PG, Czosnyka M, et al. Enhancement of cerebral blood flow using systemic hypertonic saline therapy improves outcome in patients with poor-grade spontaneous subarachnoid hemorrhage. J Neurosurg. 2007;107:274–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP. Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery. 1982;11:337–43.PubMedCrossRefGoogle Scholar
  18. 18.
    Brown FD, Hanlon K, Mullan S. Treatment of aneurysmal hemiplegia with dopamine and mannitol. J Neurosurg. 1978;49:525–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Touho H, Karasawa J, Ohnishi H, Shishido H, Yamada K, Shibamoto K. Evaluation of therapeutically induced hypertension in patients with delayed cerebral vasospasm by xenon-enhanced computed tomography. Neurol Med Chir (Tokyo). 1992;32:671–8.CrossRefGoogle Scholar
  20. 20.
    Darby JM, Yonas H, Marks EC, Durham S, Snyder RW, Nemoto EM. Acute cerebral blood flow response to dopamine-induced hypertension after subarachnoid hemorrhage. J Neurosurg. 1994;80:857–64.PubMedCrossRefGoogle Scholar
  21. 21.
    Mendelow AD, Dharker S, Patterson J, Nath F, Teasdale GM. The dopamine withdrawal test following surgery for intracranial aneurysms. J Neurol Neurosurg Psychiatry. 1986;49:35–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Otsubo H, Takemae T, Inoue T, Kobayashi S, Sugita K. Normovolaemic induced hypertension therapy for cerebral vasospasm after subarachnoid haemorrhage. Acta Neurochir (Wien). 1990;103:18–26.CrossRefGoogle Scholar
  23. 23.
    Kosnik EJ, Hunt WE. Postoperative hypertension in the management of patients with intracranial arterial aneurysms. J Neurosurg. 1976;45:148–54.PubMedCrossRefGoogle Scholar
  24. 24.
    Muizelaar JP, Becker DP. Induced hypertension for the treatment of cerebral ischemia after subarachnoid hemorrhage. Direct effect on cerebral blood flow. Surg Neurol. 1986;25:317–25.PubMedCrossRefGoogle Scholar
  25. 25.
    Miller JA, Dacey RG Jr, Diringer MN. Safety of hypertensive hypervolemic therapy with phenylephrine in the treatment of delayed ischemic deficits after subarachnoid hemorrhage. Stroke. 1995;26:2260–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Muehlschlegel S, Dunser MW, Gabrielli A, Wenzel V, Layon AJ. Arginine vasopressin as a supplementary vasopressor in refractory hypertensive, hypervolemic, hemodilutional therapy in subarachnoid hemorrhage. Neurocrit Care. 2007;6:3–10.PubMedCrossRefGoogle Scholar
  27. 27.
    Origitano TC, Wascher TM, Reichman OH, Anderson DE. Sustained increased cerebral blood flow with prophylactic hypertensive hypervolemic hemodilution (“triple-H” therapy) after subarachnoid hemorrhage. Neurosurgery. 1990;27:729–39. discussion 39-40.PubMedCrossRefGoogle Scholar
  28. 28.
    Joseph M, Ziadi S, Nates J, Dannenbaum M, Malkoff M. Increases in cardiac output can reverse flow deficits from vasospasm independent of blood pressure: a study using xenon computed tomographic measurement of cerebral blood flow. Neurosurgery. 2003;53:1044–51.PubMedCrossRefGoogle Scholar
  29. 29.
    Levy ML, Rabb CH, Zelman V, Giannotta SL. Cardiac performance enhancement from dobutamine in patients refractory to hypervolemic therapy for cerebral vasospasm. J Neurosurg. 1993;79:494–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Fraticelli AT, Cholley BP, Losser MR, Saint Maurice JP, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008;39:893–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Arakawa Y, Kikuta K, Hojo M, Goto Y, Ishii A, Yamagata S. Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: report of seven cases. Neurosurgery. 2001;48:723–8.PubMedGoogle Scholar
  32. 32.
    Tranmer BI, Keller TS, Kindt GW, Archer D. Loss of cerebral regulation during cardiac output variations in focal cerebral ischemia. J Neurosurg. 1992;77:253–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Schmidt U, Bittner E, Pivi S, Marota JJ. Hemodynamic management and outcome of patients treated for cerebral vasospasm with intraarterial nicardipine and/or milrinone. Anesth Analg. 2010;110:895–902.PubMedCrossRefGoogle Scholar
  34. 34.
    Bouma GJ, Muizelaar JP. Relationship between cardiac output and cerebral blood flow in patients with intact and with impaired autoregulation. J Neurosurg. 1990;73:368–74.PubMedCrossRefGoogle Scholar
  35. 35.
    Busani S, Rinaldi L, Severino C, Cobelli M, Pasetto A, Girardis M. Levosimendan in cardiac failure after subarachnoid hemorrhage. J Trauma. 2010;68:E108–10.PubMedCrossRefGoogle Scholar
  36. 36.
    Zada G, Terterov S, Russin J, Clavijo L, Giannotta S. Cerebral vasospasm and concurrent left ventricular outflow tract obstruction: requirement for modification of hyperdynamic therapy regimen. Neurocrit Care. 2010;12:265–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Apostolides PJ, Greene KA, Zabramski JM, Fitzgerald JW, Spetzler RF. Intra-aortic balloon pump counterpulsation in the management of concomitant cerebral vasospasm and cardiac failure after subarachnoid hemorrhage: technical case report. Neurosurgery. 1996;38:1056–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Lazaridis C, Pradilla G, Nyquist PA, Tamargo RJ. Intra-aortic balloon pump counterpulsation in the setting of subarachnoid hemorrhage, cerebral vasospasm, and neurogenic stress cardiomyopathy. Case report and review of the literature. Neurocrit Care. 2010;13:101–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Hoh BL, Carter BS, Ogilvy CS. Risk of hemorrhage from unsecured, unruptured aneurysms during and after hypertensive hypervolemic therapy. Neurosurgery. 2002;50:1207–11.PubMedGoogle Scholar
  40. 40.
    Bernardini GL, Mayer SA, Kossoff SB, Hacein-Bey L, Solomon RA, Pile-Spellman J. Anticoagulation and induced hypertension after endovascular treatment for ruptured intracranial aneurysms. Crit Care Med. 2001;29:641–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Hashimoto M, Johkura K, Ichikawa T, Kojima A, Nishimura S, Shinonaga M. Conservative treatment of ruptured vertebrobasilar dissecting aneurysm. Neurol Sci. 2008;29:241–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Juvela S. Prehemorrhage risk factors for fatal intracranial aneurysm rupture. Stroke. 2003;34:1852–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Kim HC, Nam CM, Jee SH, Suh I. Comparison of blood pressure-associated risk of intracerebral hemorrhage and subarachnoid hemorrhage: Korea Medical Insurance Corporation study. Hypertension. 2005;46:393–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke. 2001;32:1176–80.PubMedCrossRefGoogle Scholar
  45. 45.
    Lall RR, Eddleman CS, Bendok BR, Batjer HH. Unruptured intracranial aneurysms and the assessment of rupture risk based on anatomical and morphological factors: sifting through the sands of data. Neurosurg Focus. 2009;26:E2.PubMedCrossRefGoogle Scholar
  46. 46.
    Nader-Sepahi A, Casimiro M, Sen J, Kitchen ND. Is aspect ratio a reliable predictor of intracranial aneurysm rupture? Neurosurgery. 2004;54:1343–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Sforza DM, Putman CM, Scrivano E, Lylyk P, Cebral JR. Blood-flow characteristics in a terminal basilar tip aneurysm prior to its fatal rupture. Am J Neuroradiol. 2010;31:1127–31.PubMedCrossRefGoogle Scholar
  48. 48.
    van der Kolk NM, Algra A, Rinkel GJ. Risk of aneurysm rupture at intracranial arterial bifurcations. Cerebrovasc Dis. 2010;30:29–35.PubMedCrossRefGoogle Scholar
  49. 49.
    Meyer R, Deem S, David Yanez N, Souter M, Lam A, Treggiari MM. Current practices of triple-H prophylaxis and therapy in patients with subarachnoid hemorrhage. Neurocrit Care. 2011;14:24–36.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Miriam M. Treggiari
    • 1
    Email author
  • Participants in the International Multi-disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage
  1. 1.Department of Anesthesiology and Pain MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations